The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2022 | CAR-T trials and research at UKW
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, gives an update of the chimeric antigen receptor T-cell (CAR-T) clinical trials and research conducted at the University Hospital of Würzburg (UKW). Dr Hudecek talks on the ongoing CARAMBA-1 trial evaluating autologous SLAMF7 CAR-Ts in multiple myeloma (NCT04499339), and comments on a novel promising target antigen for CAR-T therapy in acute myeloid leukemia (AML). He also explains that a clinical trial for a CAR-T product for breast cancer and lung cancer will be launched soon. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting in which was held virtually in 2022.
